Moreover, the upcoming development of neoadjuvant and adjuvant immunotherapy will lead to systematically look for genomic alterations in EGFR and ALK (at least) in early-stage NS-NSCLC, since ICIs should be administered only in EGFR and ALK wild-type tumors [15]. Here, EGFR is linked to non-small cell lung carcinoma.